T1	Participants 62 100	patients with HCV genotype 1 infection
T2	Participants 216 249	patients with chronic hepatitis C
T3	Participants 462 562	treatment-naive patients with HCV genotype 1 infection enrolled in a large expanded access programme
T4	Participants 572 609	Eight hundred and ninety-one patients
